CAPLIPOINT
Caplin Point Laboratories Limited
Pharmaceutical products including injectables, ophthalmics and oral solids
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
caplinpoint.net(opens the company website in a new tab)Key metrics
Price as of 2026-10-16
Stock price
₹2301.30
Market cap
17,496 Cr
Stock P/E
26.3
P/B
4.88
Dividend yield
0.3%
ROE (FY26)
17.7%
ROCE (FY26)
22.1%
Operating margin (FY26)
31.5%
Debt / equity (FY26)
0.0002
OCF / EBITDA (FY26)
68.8%
OCF / EBITDA (3Y)
64.6%
Full years shown; sign in free for the trailing twelve months. Learn about these metrics →
Price & valuation
Share price and valuation multiples (P/E, P/B and more) over time.
Loading price history…
Compare with peers
Loading peers…
What you need to know
Caplin Point Laboratories makes and sells pharmaceutical formulations, mainly to emerging markets in Latin America and Africa, with a growing business in the United States through its subsidiary Caplin Steriles Limited.
Company snapshot
30thBy market cap
Ranked among 119 companies in Pharmaceuticals.
What we see
Positives
- ✓Net margin of 29.7% — the business keeps a healthy share of every rupee it earns.
2 more signals from the filings.Sign in free to see them all
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 410 Cr | 436 Cr | 453 Cr | 459 Cr | 483 Cr | 493 Cr | 502 Cr | 510 Cr | 534 Cr | 543 Cr | 600 Cr | 610 Cr |
| Operating expenses (approx.) | 273 Cr | 293 Cr | 308 Cr | 307 Cr | 318 Cr | 331 Cr | 334 Cr | 332 Cr | 345 Cr | 353 Cr | 396 Cr | 397 Cr |
| EBITDA | 137 Cr | 142 Cr | 145 Cr | 152 Cr | 165 Cr | 162 Cr | 168 Cr | 178 Cr | 189 Cr | 190 Cr | 204 Cr | 213 Cr |
| OPM % | 33.5% | 32.7% | 32.0% | 33.1% | 34.1% | 32.9% | 33.4% | 34.8% | 35.4% | 34.9% | 34.0% | 35.0% |
| Other income | 20 Cr | 17 Cr | 17 Cr | 19 Cr | 21 Cr | 31 Cr | 26 Cr | 23 Cr | 30 Cr | 34 Cr | 28 Cr | 34 Cr |
| Interest | 0.18 Cr | 0.17 Cr | 0.15 Cr | 0.05 Cr | 0.21 Cr | 0.18 Cr | 0.17 Cr | 0.18 Cr | 0.16 Cr | 0.18 Cr | 0.36 Cr | 0.18 Cr |
| Depreciation | 12 Cr | 14 Cr | 16 Cr | 16 Cr | 17 Cr | 16 Cr | 17 Cr | 16 Cr | 18 Cr | 19 Cr | 19 Cr | 22 Cr |
| Profit before tax | 146 Cr | 145 Cr | 146 Cr | 154 Cr | 168 Cr | 177 Cr | 177 Cr | 184 Cr | 201 Cr | 204 Cr | 213 Cr | 225 Cr |
| Tax % | 20.5% | 17.6% | 17.0% | 19.1% | 22.3% | 21.0% | 17.8% | 18.3% | 20.3% | 18.7% | 19.0% | 20.5% |
| Net profit | 116 Cr | 120 Cr | 121 Cr | 125 Cr | 131 Cr | 140 Cr | 145 Cr | 151 Cr | 160 Cr | 166 Cr | 173 Cr | 179 Cr |
| EPS (₹) | ₹15.13 | ₹15.44 | ₹16.01 | ₹16.32 | ₹17.22 | ₹18.28 | ₹18.75 | ₹20.10 | ₹20.32 | ₹21.56 | ₹22.38 | ₹23.27 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 402 Cr | 540 Cr | 649 Cr | 863 Cr | 1,061 Cr | 1,269 Cr | 1,467 Cr | 1,694 Cr | 1,937 Cr | 2,187 Cr | Sign in free for the trailing twelve months |
| Operating expenses (approx.) | 277 Cr | 345 Cr | 417 Cr | 603 Cr | 733 Cr | 875 Cr | 1,026 Cr | 1,143 Cr | 1,291 Cr | 1,426 Cr | Sign in free for the trailing twelve months |
| EBITDA | 124 Cr | 195 Cr | 231 Cr | 260 Cr | 329 Cr | 395 Cr | 441 Cr | 551 Cr | 647 Cr | 761 Cr | Sign in free for the trailing twelve months |
| OPM % | 31.0% | 36.1% | 35.7% | 30.1% | 31.0% | 31.1% | 30.1% | 32.6% | 33.4% | 34.8% | Sign in free for the trailing twelve months |
| Other income | 10 Cr | 13 Cr | 19 Cr | 41 Cr | 24 Cr | 39 Cr | 56 Cr | 67 Cr | 96 Cr | 116 Cr | Sign in free for the trailing twelve months |
| Interest | 0.13 Cr | 0.06 Cr | 0.06 Cr | 0.32 Cr | 2 Cr | 0.70 Cr | 0.78 Cr | 0.78 Cr | 0.61 Cr | 0.87 Cr | Sign in free for the trailing twelve months |
| Depreciation | 13 Cr | 19 Cr | 23 Cr | 32 Cr | 37 Cr | 47 Cr | 45 Cr | 53 Cr | 66 Cr | 73 Cr | Sign in free for the trailing twelve months |
| Profit before tax | 121 Cr | 188 Cr | 227 Cr | 269 Cr | 314 Cr | 386 Cr | 451 Cr | 564 Cr | 677 Cr | 803 Cr | Sign in free for the trailing twelve months |
| Tax % | 21.0% | 23.2% | 22.2% | 20.2% | 19.8% | 20.1% | 16.5% | 18.3% | 20.0% | 19.1% | Sign in free for the trailing twelve months |
| Net profit | 96 Cr | 145 Cr | 177 Cr | 215 Cr | 251 Cr | 308 Cr | 377 Cr | 461 Cr | 541 Cr | 650 Cr | Sign in free for the trailing twelve months |
| EPS (₹) | ₹12.65 | ₹19.26 | ₹23.35 | ₹28.42 | ₹32.03 | ₹39.61 | ₹49.62 | ₹60.19 | ₹70.57 | ₹84.36 | Sign in free for the trailing twelve months |
| Dividend payout % | — | — | — | — | 1.2% | 7.4% | 8.0% | 7.4% | 7.0% | 7.0% | Sign in free for the trailing twelve months |
Sign in free for the trailing twelve months
The latest four quarters added up, next to each full year
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 15 Cr | 15 Cr | 15 Cr | 15 Cr | 15 Cr | 15 Cr | 15 Cr | 15 Cr | 15 Cr | 15 Cr |
| Reserves | 210 Cr | 349 Cr | 618 Cr | 933 Cr | 1,171 Cr | 1,469 Cr | 1,865 Cr | 2,301 Cr | 2,835 Cr | 3,571 Cr |
| Borrowings | 0.48 Cr | 0.32 Cr | 0.29 Cr | 36 Cr | 17 Cr | 0.50 Cr | 3 Cr | 1 Cr | 0.55 Cr | 0.57 Cr |
| Other liabilities | 133 Cr | 136 Cr | 109 Cr | 133 Cr | 143 Cr | 226 Cr | 281 Cr | 349 Cr | 322 Cr | 414 Cr |
| Total liabilities | 358 Cr | 500 Cr | 743 Cr | 1,126 Cr | 1,364 Cr | 1,736 Cr | 2,191 Cr | 2,697 Cr | 3,209 Cr | 4,045 Cr |
| Fixed assets (net) | 150 Cr | 167 Cr | 225 Cr | 266 Cr | 297 Cr | 277 Cr | 267 Cr | 439 Cr | 530 Cr | 547 Cr |
| CWIP | 3 Cr | 15 Cr | 10 Cr | 20 Cr | 14 Cr | 15 Cr | 220 Cr | 117 Cr | 139 Cr | 209 Cr |
| Investments | 17 Cr | 47 Cr | 70 Cr | 61 Cr | 11 Cr | 89 Cr | 230 Cr | 376 Cr | 590 Cr | 859 Cr |
| Loans & advances | — | — | 73 Cr | — | 99 Cr | 0 Cr | 0 Cr | 0 Cr | 0 Cr | 0 Cr |
| Inventories | 22 Cr | 28 Cr | 37 Cr | 238 Cr | 179 Cr | 227 Cr | 288 Cr | 363 Cr | 336 Cr | 429 Cr |
| Trade receivables | 33 Cr | 126 Cr | 160 Cr | 229 Cr | 279 Cr | 320 Cr | 394 Cr | 543 Cr | 632 Cr | 826 Cr |
| Cash & bank | 43 Cr | 62 Cr | 49 Cr | 50 Cr | 232 Cr | 151 Cr | 178 Cr | 139 Cr | 199 Cr | 94 Cr |
| Other assets | 88 Cr | 54 Cr | 119 Cr | 262 Cr | 253 Cr | 657 Cr | 614 Cr | 722 Cr | 781 Cr | 1,081 Cr |
| Total assets | 358 Cr | 500 Cr | 743 Cr | 1,126 Cr | 1,364 Cr | 1,736 Cr | 2,191 Cr | 2,697 Cr | 3,209 Cr | 4,045 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 68 Cr | 66 Cr | 83 Cr | 45 Cr | 269 Cr | 337 Cr | 272 Cr | 311 Cr | 432 Cr | 523 Cr |
| Cash from investing | -36 Cr | -69 Cr | -100 Cr | -55 Cr | -8 Cr | -271 Cr | -218 Cr | -313 Cr | -335 Cr | -582 Cr |
| Cash from financing | -7 Cr | -12 Cr | 90 Cr | 80 Cr | -24 Cr | -41 Cr | -28 Cr | -38 Cr | -38 Cr | -46 Cr |
| Net cash flow | 25 Cr | -14 Cr | 73 Cr | 70 Cr | 236 Cr | 25 Cr | 27 Cr | -39 Cr | 59 Cr | -105 Cr |
| Free cash flow (OCF − Capex) | 42 Cr | 18 Cr | 18 Cr | -32 Cr | 269 Cr | 246 Cr | 78 Cr | 165 Cr | 241 Cr | 275 Cr |
Ratios
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 53.7% | 51.7% | 35.8% | 27.2% | 25.8% | 25.6% | 23.7% | 24.1% | 23.5% | 22.1% |
| ROE % | 42.5% | 39.7% | 27.9% | 22.5% | 20.1% | 20.4% | 19.7% | 19.5% | 19.5% | 17.7% |
| Debtor days | 30 | 85 | 90 | 97 | 96 | 92 | 98 | 117 | 119 | 137 |
| Inventory days | 125 | 115 | 143 | 804 | 502 | 430 | 470 | 553 | 492 | 437 |
| Days payable | 442 | 380 | 231 | 217 | 248 | 309 | 268 | 319 | 319 | 302 |
| Cash conversion cycle | -286 | -180 | 2 | 685 | 350 | 213 | 300 | 351 | 292 | 273 |
| OCF / EBITDA % | 54.3% | 34.1% | 36.1% | 17.2% | 81.7% | 85.3% | 61.6% | 56.4% | 66.8% | 68.8% |
| OCF / EBITDA % (3 years) | — | — | 39.5% | 28.4% | 48.4% | 66.1% | 75.3% | 66.3% | 61.9% | 64.6% |
| Debt / equity | 0.0021 | 0.0009 | 0.0005 | 0.04 | 0.01 | 0.0003 | 0.0018 | 0.0005 | 0.0002 | 0.0002 |
| Current ratio | 1.58 | 2.42 | 5.73 | 5.70 | 7.23 | 6.25 | 5.80 | 5.72 | 6.97 | 6.70 |
| Net debt / EBITDA | -0.34 | — | -0.21 | — | -0.65 | -0.38 | -0.39 | -0.25 | -0.31 | -0.12 |